Evaluation of the effects of sour tea on lipid profile, insulin resistance, oxidative stress, and inflammatory markers in adult patients with metabolic syndrome

Evaluation of the effects of Hibiscus sabdariffa on lipid profile, insulin resistance, oxidative stress, and hs-CRP level in adult patients with metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201310089662N8

Enrollment

Registered

2013-12-04

Start date

2013-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome. Other disorders of lipoprotein metabolism

Interventions

Intervention 1: In group 1 capsule daily treatment will sour tea. Once a day after breakfast. Intervention 2: In the control group taking placebo capsules daily, after breakfast.

Treatment - Drugs

Placebo

In group 1 capsule daily treatment will sour tea. Once a day after breakfast

In the control group taking placebo capsules daily, after breakfast

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with metabolic syndrome according to the criteria of panel The Adult Treatment Panel III (ATP III) treatment groups were 2005 adults.These criteria include having 3 of the 5 criteria: Abdominal obesity (waist circumference more 102 cm in men and than 88 cm In women );Decrease in plasma HDL-C (men less than 40 mg/dl and in women less than 50 mg/dl); Plasma hypertriglyceridemia (greater than 150 mg/dl); Hypertension (systolic blood pressure greater than or equal to 130 mm Hg or diastolic blood pressure greater than or equal to 85 mm Hg);And abnormal blood glucose (fasting blood glucose equal to or greater than 100). exclusion criteria:People with diseases such as diabetes type 1 or 2;Thyroid disorders; nephrotic syndrome; Liver or kidney disease;Insulin, oral antidiabetic drugs;Drugs which affect blood lipid levels, such as statins;Oral contraceptive pills, hormones such as estrogen and progesterone;Smoking, alcohol and drugs;Pregnancy and lactation; drug allergy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Low-density lipoprotein (LDL). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Triglyceride (TG). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Total cholesterol (TC). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;High-density Lipoprotein(HDL). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;VLDL. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Apo-A. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;?Apo- B. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Insulin. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;FBS. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Hs-CRP. Timepoint: Baseline and one month after intervention. Method of measurement: ng/dl/ Elisa.;MDA. Timepoint: Baseline and one month after intervention. Method of measurement: ng/dl/ Elisa.	—

Measure

Time frame

Low-density lipoprotein (LDL). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Triglyceride (TG). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Total cholesterol (TC). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;High-density Lipoprotein(HDL). Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;VLDL. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Apo-A. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;?Apo- B. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Insulin. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;FBS. Timepoint: Baseline and one month after intervention. Method of measurement: mg/dL - enzymatic - photometric.;Hs-CRP. Timepoint: Baseline and one month after intervention. Method of measurement: ng/dl/ Elisa.;MDA. Timepoint: Baseline and one month after intervention. Method of measurement: ng/dl/ Elisa.

—

Secondary

Measure	Time frame
BMI. Timepoint: Baseline and one month after intervention. Method of measurement: W/M2.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026